| 000 | 01828 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513215756.0 | ||
| 264 | 0 | _c20000929 | |
| 008 | 200009s 0 0 eng d | ||
| 022 | _a0008-6363 | ||
| 024 | 7 |
_a10.1016/s0008-6363(00)00119-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHaverkamp, W | |
| 245 | 0 | 0 |
_aThe potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. _h[electronic resource] |
| 260 |
_bCardiovascular research _cAug 2000 |
||
| 300 |
_a219-33 p. _bdigital |
||
| 500 | _aPublication Type: Congress; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAction Potentials _xdrug effects |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnti-Arrhythmia Agents _xadverse effects |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xadverse effects |
| 650 | 0 | 4 |
_aAntipsychotic Agents _xadverse effects |
| 650 | 0 | 4 | _aCardiology |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDrug and Narcotic Control |
| 650 | 0 | 4 | _aEurope |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aPotassium Channels _xdrug effects |
| 650 | 0 | 4 | _aProduct Surveillance, Postmarketing |
| 650 | 0 | 4 | _aResearch |
| 650 | 0 | 4 | _aSocieties, Medical |
| 650 | 0 | 4 |
_aTorsades de Pointes _xchemically induced |
| 650 | 0 | 4 |
_aVasodilator Agents _xadverse effects |
| 700 | 1 | _aBreithardt, G | |
| 700 | 1 | _aCamm, A J | |
| 700 | 1 | _aJanse, M J | |
| 700 | 1 | _aRosen, M R | |
| 700 | 1 | _aAntzelevitch, C | |
| 700 | 1 | _aEscande, D | |
| 700 | 1 | _aFranz, M | |
| 700 | 1 | _aMalik, M | |
| 700 | 1 | _aMoss, A | |
| 700 | 1 | _aShah, R | |
| 773 | 0 |
_tCardiovascular research _gvol. 47 _gno. 2 _gp. 219-33 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0008-6363(00)00119-x _zAvailable from publisher's website |
| 999 |
_c10896394 _d10896394 |
||